256 related articles for article (PubMed ID: 29995590)
21. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
22. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
[TBL] [Abstract][Full Text] [Related]
23. Hsp90 regulation of fibroblast activation in pulmonary fibrosis.
Sontake V; Wang Y; Kasam RK; Sinner D; Reddy GB; Naren AP; McCormack FX; White ES; Jegga AG; Madala SK
JCI Insight; 2017 Feb; 2(4):e91454. PubMed ID: 28239659
[TBL] [Abstract][Full Text] [Related]
24. Rnd1 and Rnd3 targeting to lipid raft is required for p190 RhoGAP activation.
Oinuma I; Kawada K; Tsukagoshi K; Negishi M
Mol Biol Cell; 2012 Apr; 23(8):1593-604. PubMed ID: 22357615
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
26. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors.
Didiasova M; Singh R; Wilhelm J; Kwapiszewska G; Wujak L; Zakrzewicz D; Schaefer L; Markart P; Seeger W; Lauth M; Wygrecka M
FASEB J; 2017 May; 31(5):1916-1928. PubMed ID: 28148565
[TBL] [Abstract][Full Text] [Related]
27. Sustained activation of toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: possible implications in idiopathic pulmonary fibrosis.
Kirillov V; Siler JT; Ramadass M; Ge L; Davis J; Grant G; Nathan SD; Jarai G; Trujillo G
Am J Pathol; 2015 Apr; 185(4):943-57. PubMed ID: 25660181
[TBL] [Abstract][Full Text] [Related]
28. Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis.
Pardo A; Selman M
Ann Am Thorac Soc; 2016 Dec; 13 Suppl 5():S417-S421. PubMed ID: 28005427
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta1 regulates macrophage migration via RhoA.
Kim JS; Kim JG; Moon MY; Jeon CY; Won HY; Kim HJ; Jeon YJ; Seo JY; Kim JI; Kim J; Lee JY; Kim PH; Park JB
Blood; 2006 Sep; 108(6):1821-9. PubMed ID: 16705092
[TBL] [Abstract][Full Text] [Related]
30. Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options.
Hewitt RJ; Maher TM
Drugs Aging; 2019 Jun; 36(6):485-492. PubMed ID: 30864023
[TBL] [Abstract][Full Text] [Related]
31. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.
Huang Q; Chen Y; Shen S; Wang Y; Liu L; Wu S; Xu W; Zhao W; Lin M; Wu J
Aging (Albany NY); 2020 Apr; 12(7):5812-5831. PubMed ID: 32244228
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
[TBL] [Abstract][Full Text] [Related]
33. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts.
Meng C; Fan G; Liu J; Tao N; Sun T
Biochem Biophys Res Commun; 2024 Jul; 716():150020. PubMed ID: 38692011
[TBL] [Abstract][Full Text] [Related]
34. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
35. Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.
Ebener S; Barnowski S; Wotzkow C; Marti TM; Lopez-Rodriguez E; Crestani B; Blank F; Schmid RA; Geiser T; Funke M
Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L42-L55. PubMed ID: 27815256
[TBL] [Abstract][Full Text] [Related]
36. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
Stahnke T; Kowtharapu BS; Stachs O; Schmitz KP; Wurm J; Wree A; Guthoff RF; Hovakimyan M
PLoS One; 2017; 12(2):e0172592. PubMed ID: 28231275
[TBL] [Abstract][Full Text] [Related]
37. Opposing roles of p190RhoGAP and Ect2 RhoGEF in regulating cytokinesis.
Mikawa M; Su L; Parsons SJ
Cell Cycle; 2008 Jul; 7(13):2003-12. PubMed ID: 18642445
[TBL] [Abstract][Full Text] [Related]
38. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
39. Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung.
Leppäranta O; Sens C; Salmenkivi K; Kinnula VL; Keski-Oja J; Myllärniemi M; Koli K
Cell Tissue Res; 2012 Jun; 348(3):491-503. PubMed ID: 22434388
[TBL] [Abstract][Full Text] [Related]
40. Fibrotic extracellular matrix activates a profibrotic positive feedback loop.
Parker MW; Rossi D; Peterson M; Smith K; Sikström K; White ES; Connett JE; Henke CA; Larsson O; Bitterman PB
J Clin Invest; 2014 Apr; 124(4):1622-35. PubMed ID: 24590289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
